Undermining tumor angiogenesis by gene therapy: An emerging field

Current Gene Therapy

Volumn 4, Issue 3, 2004, Pages 297-308

  Indraccolo, Stefano ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Cancer gene therapy; Endostatin; Interferon; Viral vector

Indexed keywords

ALPHA2 INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BETA INTERFERON; ENDOSTATIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL TYPE; COLON ADENOCARCINOMA; DRUG MECHANISM; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; GLIOMA; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LUNG CARCINOMA; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POLYARTHRITIS; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; TUMOR CELL; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 4444296585     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523043346363     Document Type: Review

References (123)

1. Albini A., Marchisone, C., Del Grosso, F., Benelli, R., Masiello, L., Tacchetti, C., Bono, M., Ferrantini, M., Rozera, C., Truini, M., Belardelli, F., Santi, L., and Noonan, D.M. (2000) Inhibition of angiogenesis and vascular tumor growth by interferon- producing cells: A gene therapy approach. Am. J. Pathol., 156: 1381-1393.
2. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155-162.
3. Asselin-Paturel, C., Lassau, N., Guinebretiere, J. M., Zhang, J., Gay, F., Bex, F., Hallez, S., Leclere, J., Peronneau, P., Mami-Chouaib, F., and Chouaib, S. (1999) Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther., 6: 606-615.
4. Aurisicchio, L., Delmastro, P., Salucci, V., Paz, O.G., Rovere, P., Ciliberto, G., La Monica, N., and Palombo, F. (2000) Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J. Virol., 74: 4816-4823.
5. Baum, C., Ostertag, W., Stocking, C., and Von Laer, D. (2002) Retroviral Vector Design for Cancer Gene Therapy. In: Gene therapy of Cancer, Eds. Lattime E.C. & Gerson S.L., Academic Press, San Diego, pp. 3-29.
6. Belardelli, F., Ferrantini, M., Proietti, E., and Kirkwood, J. M. (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 13: 119-134.
7. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin. Invest., 103: 159-165.
8. Bloch, W., Huggel, K., Sasaki, T., Grose, R., Bugnon, P., Addicks, K., Timpl, R., and Werner, S. (2000) The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J., 14: 2373-2376.
9. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390: 404-407.
10. Bouck, N., Stellmach, V., and Hsu, S. C. (1996) How tumors become angiogenic. Adv. Cancer Res., 69: 135-174.
11. Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., and Cheresh, D. A. (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell, 92: 391-400.
12. Calvo, A., Feldman, A. L., Libutti, S. K., and Green, J. E. (2002) Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. Cancer Res., 62: 3934-3938.
13. Chen, C. T., Lin, J., Li, Q., Phipps, S. S., Jakubczak, J. L., Stewart, D. A., Skripchenko, Y., Forry-Schaudies, S., Wood, J., Schnell, C., and Hallenbeck, P. L. (2000) Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene Ther., 11: 1983-1996.
14. Chen, Q. R., Kumar, D., Stass, S. A., and Mixson, A. J. (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res., 59: 3308-3312.
15. Clackson, T. (1997) Controlling mammalian gene expression with small molecules. Curr. Opin. Chem. Biol., 1: 210-218.
16. D'Angelo, G., Struman, I., Martial, J., and Weiner, R. I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N- terminal fragment of prolactin. Proc. Natl. Acad. Sci. USA, 92: 6374-6378.
17. De Bouard, S., Guillamo, J.S., Christov, C., Lefevre, N., Brugieres, P., Gola, E., Devanz, P., Indraccolo, S., and Peschanski, M. (2003) Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum. Gene Ther., 14: 883-895.
18. De Palma, M., Venneri, M.A., Roca, C., and Naldini, L. (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med., 9: 789-795.
19. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon- alpha administration. Cancer Res., 58: 808-814.
20. Dong, Z., Greene, G., Pettaway, C., Dinney, C. P., Eue, I., Lu, W., Bucana, C. D., Balbay, M. D., Bielenberg, D., and Fidler, I. J. (1999) Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res., 59: 872-879.
21. Dubois, J., Hershon, L., Carmant, L., Belanger, S., Leclerc, J. M., and David, M. (1999) Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J. Pediatr., 135: 782-785.
22. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393.
23. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D., and Eaves, C. (2002) Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther., 5: 352-359.
24. Feldman, A. L., Alexander, H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., and Libutti, S. K. (2001) Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst., 93: 1014-1020.
25. Feldman, A. L., Friedl, J., Lans, T. E., Libutti, S. K., Lorang, D., Miller, M. S., Turner, E. M., Hewitt, S. M., and Alexander, H. R. (2002) Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int. J. Cancer, 99: 149-153.
26. Feldman, A. L., and Libutti, S. K. (2000) Progress in antiangiogenic gene therapy of cancer. Cancer, 89: 1181-1194.
27. Feldman, A. L., Restifo, N. P., Alexander, H. R., Bartlett, D. L., Hwu, P., Seth, P., and Libutti, S. K. (2000) Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res., 60: 1503-1506.
28. Ferrantini, M., and Belardelli, F. (2000) Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol., 10: 145-157.
29. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6.
30. Folkman, J. (1995a) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31.
31. Folkman, J. (1995b) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763.
32. Folkman, J. (1998) Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95: 9064-9066.
33. Freeman, M. R., Schneck, F. X., Gagnon, M. L., Corless, C., Soker, S., Niknejad, K., Peoples, G. E., and Klagsbrun, M. (1995) Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res., 55: 4140-4145.
34. Friesel, R., Komoriya, A., and Maciag, T. (1987) Inhibition of endothelial cell proliferation by gamma-interferon. J. Cell Biol., 104: 689-696.
35. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725.
36. Griscelli, F., Li, H., Bennaceur-Griscelli, A., Soria, J., Opolon, P., Soria, C., Perricaudet, M., Yeh, P., and Lu, H. (1998) Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA, 95: 6367-6372.
37. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C.J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K.W., and Geissler, E.K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8: 128-135.
38. Gyorffy, S., Palmer, K., Podor, T. J., Hitt, M., and Gauldie, J. (2001) Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J. Immunol., 166: 6212-6217.
39. Halin, C., Rondini S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol., 20: 264-269.
40. Hammani, K., Blakis, A., Morsette, D., Bowcock, A. M., Schmutte, C., Henriet, P., and DeClerck, Y. A. (1996) Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J. Biol. Chem., 271: 25498-25505.
41. Hampl, M., Tanaka, T., Albert, P. S., Lee, J., Ferrari, N., and Fine, H. A. (2001) Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum. Gene Ther., 12: 1713-1729.
42. Harrington, K., Alvarez-Vallina, L., Crittenden, M., Gough, M., Chong, H., Diaz, R. M., Vassaux, G., Lemoine, N., and Vile, R. (2002) Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum. Gene Ther., 13: 1263-1280.
43. Hasumi, Y., Mizukami, H., Urabe, M., Kohno, T., Takeuchi, K., Kume, A., Momoeda, M., Yoshikawa, H., Tsuruo, T., Shibuya, M., Taketani, Y., and Ozawa, K. (2002) Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res., 62: 2019-2023.
44. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L.M., Pluda, J., Hong, W. K., and Abruzzese, J. L. (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 20: 3792-3803.
45. Huang, S., Xie, K., Bucana, C. D., Ullrich, S. E., and Bar-Eli, M. (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res., 2: 1969-1979.
46. Indraccolo, S., Gola, E., Rosato, A., Minuzzo, S., Habeler, W., Tisato, V., Roni, V., Esposito, G., Morini, M., Albini, A., Noonan, D. M., Ferrantini, M., Amadori, A., and Chieco-Bianchi, L. (2002a) Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther., 9: 867-878.
47. Indraccolo, S., Habeler, W., Tisato, V., Stievano, L., Piovan, E., Tosello, V., Esposito, G., Wagner, R., Uberla, K., Chieco-Bianchi, L., and Amadori, A. (2002b) Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res., 62: 6099-6107.
48. Indraccolo, S., Minuzzo, S., Roccaforte, F., Zamarchi, R., Habeler, W., Stievano, L., Tosello, V., Klein, D., Gunzburg, W. H., Basso, G., Chieco-Bianchi, L., Amadori, A. (2001a) Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 98: 3607-3617.
49. Indraccolo, S., Morini, M., Gola, E., Carrozzino, F., Habeler, W., Minghelli, S., Santi, L., Chieco-Bianchi, L., Cao, Y., Albini, A., and Noonan, D. M. (2001b) Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res., 61: 5441-5446.
50. Introna, M., Barbui, A. M., Bambacioni, F., Casati, C., Gaipa, G., Borleri, G., Bernasconi, S., Barbui, T., Golay, J., Biondi, A., and Rambaldi, A. (2000) Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther., 11: 611-620.
51. Izawa, J. I., Sweeney, P., Perrotte, P., Kedar, D., Dong, Z., Slaton, J. W., Karashima, T., Inoue, K., Benedict, W. F., and Dinney, C. P. (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin. Cancer Res., 8: 1258-1270.
52. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., and Black, P. M. (2001) Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35-39.
53. Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S. S., Lee, M, H., Park, K., Kim, K., Jeong, H. S., Kim, J. A., Nam, S. J., Yang, J. H., Son, Y. I., Baek, C. H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D. W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J. H., park, M. H., Kong, G. S., Park, E. Y., Kamg, Y. K., Bang, Y. J., Paik, N. S., Lee, S. N., Kim, S. H., Robbins, P. D., Tahara, H., Lotze, M. T., and Park, C. H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther., 12: 671-684.
54. Kendall, R. L., Wang, G., and Thomas, K. A. (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun., 226: 324-328.
55. Kerbel, R., and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2: 727-739.
56. Killion, J. J., Radinsky, R., and Fidler, I. J. (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev., 17: 279-284.
57. Kleinman, H. K., and Liau, G. (2001) Gene therapy for antiangiogenesis. J Natl. Cancer Inst., 93: 965-967.
58. Klimp, A. H., de Vries, E. G., Scherphof, G. L., and Daemen, T. (2002) A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol., 44: 143-161.
59. Kong, H. L., and Crystal, R. G. (1998) Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst., 90: 273-286.
60. Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., Westphal, M., and Lamszus, K. (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res., 61: 6624-6628.
61. Kuo, C. J., Farnebo, F., Yu, E, Y., Christofferson, R., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, L, Kamihara, J., Flynn, E., D'Amato, R., Folkman, J., and Mulligan, R. C. (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA, 98: 4605-4610.
62. Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A., and Paller, A. S. (1997) Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res., 57: 5277-5280.
63. Liau, G., Su, E. J., and Dixon, K. D. (2001) Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. Drug Discov. Today, 6: 689-697.
64. Liu, Y., Thor, A., Shtivelman, E., Cao, Y., Tu, G., Heath, T. D., and Debs, R. J. (1999) Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem., 274: 13338-13344.
65. Lohr, M., Hoffmeyer, A., Kroger, J., Freund, M., Hain, J., Holle, A., Karle, P., Knofel, W. T., Liebe, S., Muller, P., Nizze, H., Renner, M., Saller, R. M., Wagner, T., Hauenstein, K., Gunzburg, W. H., and Salmons, B. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet, 357: 1591-1592.
66. Lohr, M., Muller, P., Karle, P., Stange, J., Mitzner, S., Jesnowski, R., Nizze, H., Nebe, B., Liebe, S., Salmons, B., and Gunzburg, W. H. (1998) Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther., 5: 1070-1078.
67. Ma, H. I., Guo, P., Li, J., Lin, S. Z., Chiang, Y. H., Xiao, X., and Cheng, S. Y. (2002) Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res., 62: 756-763.
68. Mahasreshti, P. J., Navarro, J. G., Kataram, M., Wang, M. H., Carey, D., Siegal, G. P., Barnes, M. N., Nettelbeck, D. M., Alvarez, R. D., Hemminki, A., and Curiel, D. T. (2001) Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res., 7: 2057-2066.
69. Maione, D., Della Rocca, C., Giannetti, P., D'Arrigo, R,, Liberatoscioli, L., Franlin, L.L., Sandig, V., Ciliberto, G., La Monica, N., and Savino, R. (2001) An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. USA, 98: 5986-5991.
70. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., and Sharpe, R. J. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science, 247: 77-79.
71. Marler, J. J., Rubin, J. B., Trede, N. S., Connors, S., Grier, H., Upton, J., Mulliken, J. B., and Folkman, J. (2002) Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics, 109: E37.
72. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367: 576-579.
73. Miller, N., and Whelan, J. (1997) Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther., 8: 803-815.
74. Monahan, P.E., and Samulski, R.J. (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol. Med. Today, 6: 433-440.
75. Moses, M. A., Sudhalter, J., and Langer, R. (1992) Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J. Cell Biol., 119: 475-482.
76. Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. (2000) Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol., 18: 1135-1149.
77. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwilliger, E. F. (1999) Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res., 58: 5673-5677.
78. Nilsson, F., Kosmehl, H., Zardi, L., and Neri, D. (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res., 61: 711-716.
79. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J. (1992) Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053.
80. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285.
81. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328.
82. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J. (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science, 285: 1926-1928.
83. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. (2002) Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther., 5: 345-351.
84. Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D. A., and Verma, I. M. (2000) Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA, 97: 12227-12232.
85. Pollock, R., Issner, R., Zoller, K., Natesan, S., Rivera, V. M., and Clackson, T. (2000) Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc. Natl. Acad. Sci. USA, 97: 13221-13226.
86. Qin, X. Q., Tao, N., Dergay, A., Moy, P., Fawell, S., Davis, A., Wilson, J. M., and Barsoum, J. (1998) Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA, 95: 14411-14116.
87. Read, T. A., Sorensen, D. R., Mahesparan, R., Enger, P. O., Timpl, R., Olsen, B. R., Hjelstuen, M. H., Haraldseth, O., and Bjerkvig, R. (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol., 19: 29-34.
88. Regulier, E., Paul, S., Marigliano, M., Kintz, J., Poitevin, Y., Ledoux, C., Roecklin, D., Cauet, G., Calenda, V., and Homann, H. E. (2001) Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther., 8: 45-54.
89. Rigg, A. S., and Lemoine, N. R. (2001) Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther., 8: 869-878.
90. Risau, W. (1997) Mechanisms of angiogenesis. Nature, 386: 671-674.
91. Roni, V., Habeler, W., Parenti, A., Indraccolo, S., Gola, E., Tosello, V., Cortivo, R., Abatangelo, G., Chieco-Bianchi, L., and Amadori, A. (2003) Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Exp. Cell Res., 287: 28-38.
92. Rozera, C., Carlei, D., Lollini, P. L., De Giovanni, C., Musiani, P., Di Carlo, E., Belardelli, F., and Ferrantini, M. (1999) Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am. J. Pathol., 154: 1211-1222.
93. Sacco, M. G., Caniatti, M., Cato, E. M., Frattini, A., Chiesa, G., Ceruti, R., Adorni, F., Zecca, L., Scanziani, E., and Vezzoni, P. (2000) Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res., 60: 2660-2665.
94. Sacco, M. G., Cato, E. M., Ceruti, R., Soldati, S., Indraccolo, S., Caniatti, M., Scanziani, E., and Vezzoni, P. (2001) Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther., 8: 67-70.
95. Sacco, M. G., Soldati, S., Mira Cato, E., Cattaneo, L., Pratesi, G., Scanziani, E., and Vezzoni, P. (2002) Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTVneu mice. Gene Ther., 9: 1338-1341.
96. Sadelain, M., and Riviere, I. (2002) The Advent of Lentiviral Vectors: Prospects for Cancer Therapy. Gene therapy of Cancer. In: Gene therapy of Cancer, Eds. Lattime E.C. & Gerson S.L., Academic Press, San Diego, pp109-124.
97. Santodonato, L., Ferrantini, M., Palombo, F., Aurisicchio, L., Delmastro, P., La Monica, N., Di Marco, S., Ciliberto, G., Du, M. X., Taylor, M. W., and Belardelli, F. (2001) Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Ther., 8: 63-72.
98. Sauter, B. V., Martinet, O., Zhang, W. J., Mandeli, J., and Woo, S. L. (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA, 97: 4802-4807.
99. Scappaticci, F. A. (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol, 20: 3906-3927.
100. Scappaticci, F. A., Smith, R., Pathak, A., Schloss, D., Lum, B., Cao, Y., Johnson, F., Engleman, E. G., and Nolan, G. P. (2001) Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther., 3: 186-196.
101. Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., Koniaris, L. G., Vanguri, P., Burd, P. R., Sheikh, N., Gupta, G., Teruya-Feldstein, J., and Tosato, G. (1996a) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA, 93: 13791-13796.
102. Sgadari, C., Angiolillo, A. L., and Tosato, G. (1996b) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 87: 3877-3882.
103. Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., and Tosato, G. (1997) Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood, 89: 2635-2643.
104. Shi, W., Teschendorf, C., Muzyczka, N., and Siemann, D. W. (2002) Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther., 9: 513-521.
105. Shi, W., Teschendorf, C., Muzyczka, N., and Siemann, D. W. (2003) Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol., 66: 1-9.
106. Shichinohe, T., Bochner, B. H., Mizutani, K., Nishida, M., Hegerich-Gilliam, S., Naldini, L., and Kasahara, N. (2001) Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther., 8: 879-889.
107. Sidky, Y. A., and Borden, E. C. (1987) Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155-5161.
108. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. (1995) Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566.
109. Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., and Martial, J. A. (1999) Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA, 96: 1246-1251.
110. Tada, H., Maron, D. J., Choi, E. A., Barsoum, J., Lei, H., Xie, Q., Liu, W., Ellis, L., Moscioni, A. D., Tazelaar, J., Fawell, S., Qin, X., Propert, K. J., Davis, A., Fraker, D. L., Wilson, J. M., and Spitz, F. R. (2001) Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J. Clin. Invest., 108: 83-95.
111. Tanaka, T., Manome, Y., Wen, P., Kufe, D. W., and Fine, H. A. (1997) Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med., 3: 437-442.
112. Tuting, T., Gambotto, A., Baar, J., Davis, I. D., Storkus, W. J., Zavodny, P. J., Narula, S., Tahara, H., Robbins, P. D., and Lotze, M. T. (1997) Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther., 4: 1053-1060.
113. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst., 87: 581-586.
114. Volpert, O. V., Fong, T., Koch, A. E., Peterson, J. D., Waltenbaugh, C., Tepper, R. I., and Bouck, N. P. (1998) Inhibition of angiogenesis by interleukin 4. J. Exp. Med., 188: 1039-1046.
115. Volpert, O. V., Tolsma, S. S., Pellerin, S., Feige, J. J., Chen, H., Mosher, D. F., and Bouck, N. (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Commun., 217: 326-332.
116. von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., and Rosewicz, S. (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst., 95: 437-448.
117. Wen, X. Y., Bai, Y., and Stewart, A. K. (2001) Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther., 12: 347-358.
118. Wu, Q., Moyana, T., and Xiang, J. (2001) Cancer gene therapy by adenovirus-mediated gene transfer. Curr. Gene Ther., 1: 101-122.
119. Xu, M., Kumar, D., Stass, S. A., and Mixson, A. J. (1998) Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo. Mol. Genet. Metab., 63: 103-109.
120. Yamanaka, R., Zullo, S. A., Ramsey, J., Onodera, M., Tanaka, R., Blaese, M., and Xanthopoulos, K. G. (2001) Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther., 8: 796-802.
121. Yang, W., Arii, S., Mori, A., Furumoto, K., Nakao, T., Isobe, N., Murata, T., Onodera, H., and Imamura, M. (2001) sFlt-1 gene-transfected fibroblasts: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res., 61: 7840-7845.
122. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science, 295: 1526-1528.
123. Zhang, J. F., Hu, C., Geng, Y., Blatt, L. M., and Taylor, M. W. (1996) Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. Cancer Gene Ther., 3: 31-38.